Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Entera Bio Ltd.NASDAQ: ENTX
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 18.0% from a year ago
Other current liabilities stood at $453K at the end of Q1 FY2026, up 18.0% from a year earlier and up 4.9% from the prior quarter. Over 3 fiscal years it compounded at +12.9% a year.
Context
- Other current liabilities amounted to 3.5% of total assets at the end of Q1 FY2026, up 1.7 pp from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +18.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 432K USD
- Year-over-year change
- +27.4%
- 4-year CAGR
- -1.3%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 432K | +27.4% |
| FY2024 | 2024-12-31 | 339K | -32.2% |
| FY2023 | 2023-12-31 | 500K | +66.7% |
| FY2022 | 2022-12-31 | 300K | -34.1% |
| FY2021 | 2021-12-31 | 455K | — |
Other Current Liabilities vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's Mar 2026 other current liabilities of $453K is the 7th highest of the 10 companies compared; the peer median is $3M.
- Its year-over-year change of +18.0% is the 5th highest of 9, against a peer median of -21.6%.
- Other current liabilities amounts to 3.5% of total assets for ENTX, versus a peer median of 1.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $28.15M | -74.2% | -6.4% | 15.1% | |
| Mar 2026 | $27.02M | +70.3% | +34.0% | 54.3% | |
| Mar 2026 | $4.3M | +63.4% | -49.2% | 3.7% | |
IRDOpus Genetics, Inc. | Mar 2026 | $4.12M | -67.6% | — | 6.2% |
| Mar 2026 | $3M | +101.8% | -3.9% | 1.1% | |
| Mar 2026 | $1.61M | +24.3% | +218.8% | 1.2% | |
| Mar 2026 | $453K | +18.0% | +12.9% | 3.5% | |
| Mar 2026 | $197.59K | -86.4% | +31.2% | 0.7% | |
| Apr 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | -7.4% | 0.0% | |
| Peer median (excluding ENTX) | $3M | -21.6% | -3.9% | 1.2% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.